Evaluation of GLYPICAN-3 as ANovel Diagnostic Marker for Hepatocellular Carcinoma
Ahmed Mohamed Abd El Sameaa khattab;
Abstract
SUMMARY
H
epatocellular carcinoma is one of the most common malignancies in the world.Until recently; alpha feto protein (AFP) has been the most widely used plasma marker for diagnosis, surveillance and as a prognostic indicator of HCC patients’ survival.
Several tumor markers have been proposed as complement or substitute for AFP in HCC diagnosis. Recently, lens culinaris agglutinin-reactive fraction of AFP (AFP-L3) and des gamma carboxy prothrombin have been approved by the FDA as plasma markers for HCC. AFP-L3 can be detected in the plasma of patients with small tumors.
Another potential biomarker for HCC is Glypican 3 (GPC3) is one of the cell surface heparan sulfate proteoglycans that bind to the cell membrane via glycosil phosphatidyl inositol anchors. While studies on ovarian cancer cell lines, mesotheliomas, and breast tumors have demonstrated the down regulation of GPC3, other investigations on hepatocellular carcinoma have shown a marked elevation of GPC3 mRNA over the level observed in corresponding normal tissues.
The aim of this study is to evaluate the use of GPC3 as novel diagnostic markers for the diagnosis of HCC in comparison with alpha feto protein.
This study included two groups:
Group (I): 40 patients with liver cirrhosis and hepatocellular carcinoma.
Group (II): 40 patients with liver cirrhosis only.
Group (I) included 19 males (47.5%) and 21 females (52.5%) with mean age 55.15 ± 8.6 yrs, of which 27 patients were HCV+ve and 9 patients HBV+ve and 3 patients were HBV ,HCV +ve and 1 patient had –ve virology while group (II) included 22 males (55%) and 18 females (45%) with mean age 52.85±7.02 yrs of which 26 patients were HCV+ve and 10 patients HBV+Ve and 2 patients were HBV ,HCV +ve and 2 patient had –ve virology .
According to the Child-classification group (I) included 6 patients who were categorized as Child A (15%), 14 patients as Child B (35%) and 20 patients as Child C (50%) while group (II) included 13 patients who were categorized as Child A (32.5%), 14 patients as Child B (50%) and 13 patients as Child C (32.5%).
All patients were negative for Cancer ovary, Cancer breast and Cancer pancreas by clinical examination and pelviabdominal CT with no renal impairment.
In our study we found that there were no statistically significant differences between the two groups regarding the Hb, Plt, albumin, ALT, AST, and T.bil. While there was significant differences between the two groups regarding the ALP .
H
epatocellular carcinoma is one of the most common malignancies in the world.Until recently; alpha feto protein (AFP) has been the most widely used plasma marker for diagnosis, surveillance and as a prognostic indicator of HCC patients’ survival.
Several tumor markers have been proposed as complement or substitute for AFP in HCC diagnosis. Recently, lens culinaris agglutinin-reactive fraction of AFP (AFP-L3) and des gamma carboxy prothrombin have been approved by the FDA as plasma markers for HCC. AFP-L3 can be detected in the plasma of patients with small tumors.
Another potential biomarker for HCC is Glypican 3 (GPC3) is one of the cell surface heparan sulfate proteoglycans that bind to the cell membrane via glycosil phosphatidyl inositol anchors. While studies on ovarian cancer cell lines, mesotheliomas, and breast tumors have demonstrated the down regulation of GPC3, other investigations on hepatocellular carcinoma have shown a marked elevation of GPC3 mRNA over the level observed in corresponding normal tissues.
The aim of this study is to evaluate the use of GPC3 as novel diagnostic markers for the diagnosis of HCC in comparison with alpha feto protein.
This study included two groups:
Group (I): 40 patients with liver cirrhosis and hepatocellular carcinoma.
Group (II): 40 patients with liver cirrhosis only.
Group (I) included 19 males (47.5%) and 21 females (52.5%) with mean age 55.15 ± 8.6 yrs, of which 27 patients were HCV+ve and 9 patients HBV+ve and 3 patients were HBV ,HCV +ve and 1 patient had –ve virology while group (II) included 22 males (55%) and 18 females (45%) with mean age 52.85±7.02 yrs of which 26 patients were HCV+ve and 10 patients HBV+Ve and 2 patients were HBV ,HCV +ve and 2 patient had –ve virology .
According to the Child-classification group (I) included 6 patients who were categorized as Child A (15%), 14 patients as Child B (35%) and 20 patients as Child C (50%) while group (II) included 13 patients who were categorized as Child A (32.5%), 14 patients as Child B (50%) and 13 patients as Child C (32.5%).
All patients were negative for Cancer ovary, Cancer breast and Cancer pancreas by clinical examination and pelviabdominal CT with no renal impairment.
In our study we found that there were no statistically significant differences between the two groups regarding the Hb, Plt, albumin, ALT, AST, and T.bil. While there was significant differences between the two groups regarding the ALP .
Other data
| Title | Evaluation of GLYPICAN-3 as ANovel Diagnostic Marker for Hepatocellular Carcinoma | Other Titles | تقييـــم استخــدام الجليبيكــان 3 كدليـــل أورام جديد لتشخيص سرطان الكبد | Authors | Ahmed Mohamed Abd El Sameaa khattab | Issue Date | 2016 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.